Munich, October 10-13th 2019: Defymed’s CEO, Séverine Sigrist and COO, Richard Bouaoun are glad to participate to the 15th IXA (International Xenotransplantation Association) congress that will be held in Munich – Germany from October 10 till October 13. This congress gathers key opinion leaders and top notch research around xenotransplantation in several therapeutic fields, worldwide.
Defymed has been chosen to present the latest advances on the cell-encapsulation platform, MailPan®, towards a safer and more efficient cell therapy for patients suffering with chronic diseases. We are proud to annouce that we will present MailPan® during an oral sessions on saturday 13th during the latest session of the day titled: Rapid-Fire Abstract Session on Islet and Non-Islet Cell Transplantation. The title of our presentation is: Validation of Safety and Function of a new macroencapsulation device in small and large animal models
For more information about IXA: http://ixa2019.org/